Format

Send to

Choose Destination
Trials. 2018 Jul 31;19(1):413. doi: 10.1186/s13063-018-2784-3.

Assessment of the effect of addition of 24 hours of oral tranexamic acid post-operatively to a single intraoperative intravenous dose of tranexamic acid on calculated blood loss following primary hip and knee arthroplasty (TRAC-24): a study protocol for a randomised controlled trial.

Author information

1
Primary Joint Unit, Musgrave Park Hospital, Belfast Health and Social Care Trust, Stockman's Lane, Belfast, BT9 7JB, UK. janet.hill@belfasttrust.hscni.net.
2
Primary Joint Unit, Musgrave Park Hospital, Belfast Health and Social Care Trust, Stockman's Lane, Belfast, BT9 7JB, UK.
3
Theatres, Musgrave Park Hospital, Belfast Health and Social Care Trust, Stockman's Lane, Stockman's Lane, Belfast, BT9 7JB, UK.
4
Department of Anaesthesia, Ulster Hospital, Upper Newtownards Road, Dundonald, Belfast, BT16 1RH, UK.
5
Department of Haematology, Tower block, Belfast City Hospital, Belfast Health and Social Care Trust, 51 Lisburn Road, Belfast, BT9 7AB, UK.
6
Pharmacy Department, The Royal Hospitals, Belfast Health and Social Care Trust Grosvenor Road, Belfast, BT12 6BA, UK.
7
Northern Ireland Clinical Trials Unit (NICTU), The Royal Hospitals, 1st Floor Elliott Dynes Building, Grosvenor Road, Belfast, BT12 6BA, UK.

Abstract

BACKGROUND:

While it is has been proven that tranexamic acid (TXA) reduces blood loss in primary total hip and knee arthroplasty (THA and TKA), there is little published evidence on the use of TXA beyond 3 h post-operatively. Most blood loss occurs after wound closure and the primary aim of this study is to determine if the use of oral TXA post-operatively for up to 24 h will reduce calculated blood loss at 48 h beyond an intra-operative intravenous bolus alone following primary THA and TKA. To date, most TXA studies have excluded patients with a history of thromboembolic disease.

METHODS/DESIGN:

This is a phase IV, single-centred, open-label, parallel-group, randomised controlled trial. Participants are randomised to one of three groups: group 1, an intravenous (IV) bolus of TXA peri-operatively plus oral TXA post-operatively for 24 h; group 2, an IV bolus of TXA peri-operatively or group 3, standard care (no TXA). Eligible participants, including those with a history of thromboembolic disease, are allocated to these groups with a 2:2:1 allocation ratio. The primary outcome is the indirectly calculated blood loss 48 h after surgery. Researchers and patients are not blinded to the treatment; however, staff processing blood samples are. Originally 1166 participants were required to complete this study, 583 THA and 583 TKA. However, following an interim analysis after 100 THA and 100 TKA participants had been recruited to the study, the data monitoring ethics committee recommended stopping group 3 (standard care).

DISCUSSION:

TRAC-24 will help to determine whether an extended TXA dosing regimen can further reduce blood loss following primary THA and TKA. By including patients with a history of thromboembolic disease, this study will add to our understanding of the safety profile of TXA in this clinical situation.

TRIAL REGISTRATION:

ISRCTN registry, ISRCTN58790500 . Registered on 3 June 2016, EudraCT: 2015-002661-36.

KEYWORDS:

Arthroplasty; Blood loss; Hip; Knee; Oral; Post-operative; Replacement; Tranexamic acid

PMID:
30064517
PMCID:
PMC6069723
DOI:
10.1186/s13063-018-2784-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center